Stereotactic Advanced-imaging Guided Radiotherapy For GlioblastomA (SAGA 2.0)

Overview

About this study

Cohort 1 is a phase III design randomized trial of patients with newly diagnosed glioblastoma with a primary endpoint to determine whether overall survival is significantly improved with dose-intensified radiation over accelerated radiation.

Cohort 2 includes patients with glioblastoma who are not eligible for six weeks of radiation and therefore not eligible for Cohort 1. Cohort 2 is a Bayesian design trial to determine if intensified accelerated radiation improves survival compared to accelerated radiation. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age ≥18 years.

  • Histological confirmation of glioblastoma (IDH-wildtype).

  • ECOG Performance Status (PS) ≤3 (Appendix I) at baseline.

  • Provide written informed consent or have a Legally Authorized Representative (LAR) who is responsible for the care and well-being of the potential study participant, provide consent in accordance with ethical, regulatory, and institutional requirements.

  • Ability to complete questionnaire(s) by themselves or with assistance.

  • Willing to return to enrolling institution for follow-up either in-person or by video visit.

  • Willing to consent to and provide mandatory blood samples for correlative research purposes.

Exclusion Criteria:

  • Known to be pregnant or nursing

  • Unable to undergo MRI scans with contrast (such as patients with devices or metal in head that is MRI incompatible)

  • Unable to undergo 18FET/PET scan (such as allergy to the contrast/tracer, technical, patient factors or limits per the discretion of the treating physician)

  • Prior radiation or chemotherapy for glioblastoma (note: prior cancer diagnoses and treatment for other cancers are not exclusion criteria, and multiple surgeries prior to enrollment is not an exclusion criteria)

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

 Eligibility last updated 06/17/2026. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Mankato, Minn.

Mayo Clinic principal investigator

Jason Hayes, M.D.

Contact us for the latest status

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Rochester, Minn.

Mayo Clinic principal investigator

William Breen, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Jacksonville, Fla.

Mayo Clinic principal investigator

Daniel Trifiletti, M.D.

Contact us for the latest status

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

La Crosse, Wis.

Mayo Clinic principal investigator

Abigail Stockham, M.D.

Contact us for the latest status

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Sujay Vora, M.D.

Contact us for the latest status

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Eau Claire, Wis.

Mayo Clinic principal investigator

Now Bahar Alam, M.D.

Contact us for the latest status

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Albert Lea, Minn.

Mayo Clinic principal investigator

John Yeakel, M.D.

Contact us for the latest status

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available
.
CLS-20611958

Mayo Clinic Footer